| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702337 | Surgical Oncology | 2017 | 7 Pages |
Abstract
LVSI status remains a strong prognostic factor in high-risk ECs associated with a higher recurrence rate and lower RFS and OS whatever the histological type and lymph node status. It could thus be considered in future trials to guide decision-making about adjuvant therapy in high-risk ECs.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Sofiane MD, PhD, Morgane MD, Lobna MD, PhD, Vincent MD, PhD, Geoffroy MD, Emilie MD, Delphine MD, Charles MD, PhD, Olivier MD, PhD, Cyril MD, PhD, Pierre MD, PhD, Emile MD, PhD, Marcos M.D, PhD,